SCHEMBL16211484

SCHEMBL16211484

CCn1cnc2c(N3CCC(O)C3)nc(C(C)(C)C)nc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16211861 0.91 CNR2 (1.00) CNR2
SCHEMBL16211979 0.88 CNR2 (1.00) CNR2
SCHEMBL16211568 0.88 CNR2 (1.00) CNR2
SCHEMBL16211521 0.86 CNR2 (1.00) CNR2
SCHEMBL16211523 0.86 CNR2 (1.00) CNR2
SCHEMBL16211631 0.86 CNR2 (1.00) CNR2
SCHEMBL16212006 0.84 CNR2 (0.73) CNR2
SCHEMBL16211827 0.84 CNR2 (1.00) CNR2
SCHEMBL16211712 0.84 CNR2 (1.00) CNR2
SCHEMBL16211824 0.84 CNR2 (1.00) CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991987-B1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2018-05-23 EP claimed
US-9505762-B2 Purine derivatives as CB2 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2016-11-29 US claimed
EP-2991987-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2016-03-09 EP claimed
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN-LA ROCHE INC. (US) 2016-02-18 US claimed
WO-2014177490-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO claimed
EP-2991987-B1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2018-05-23 EP disclosed
EP-2991987-B1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2018-05-23 EP disclosed
US-9505762-B2 Purine derivatives as CB2 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2016-11-29 US disclosed
US-9505762-B2 Purine derivatives as CB2 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2016-11-29 US disclosed
US-9505762-B2 Purine derivatives as CB2 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2016-11-29 US disclosed
EP-2991987-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2016-03-09 EP disclosed
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN-LA ROCHE INC. (US) 2016-02-18 US disclosed
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN-LA ROCHE INC. (US) 2016-02-18 US disclosed
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS HOFFMANN-LA ROCHE INC. (US) 2016-02-18 US disclosed
WO-2014177490-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed
WO-2014177490-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046631-A1 PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS CNR1, CNR2, P2RY1 CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.